HER2 Guidelines for Breast Cancer Could Misclassify Some Patients

The American Society of Clinical Oncology-College of American Pathologists (ASCO-CAP) guidelines for HER2 gene amplification testing may leave some patients at risk for misclassification and inappropriate treatment according to a recent report from the Norris Comprehensive Cancer Center, Keck School of Medicine of the University of Southern California in Los Angeles.

 Cancer Network